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a b s t r a c t
Aims: Treatment with glucocorticoids for neoplasms and inflammatory disorders is fre-
quently complicated by glucocorticoid induced hyperglycaemia (GCIH). GCIH is associated
with adverse outcomes and its treatment has short term and long term benefits. Currently,
treatment targets and modalities depend on local protocols and habits of individual
clinicians. We explored current practice of screening and treatment of GCIH in patients
receiving glucocorticoid pulse therapy.
Methods: A factorial survey with written case vignettes. All vignette patients received
glucocorticoid pulse therapy. Other characteristics (e.g., indication for glucocorticoid ther-
apy, pre-existent diabetes) varied. The survey was held between November 2013 and May
2014 on 2 nationwide conferences and in hospitals across The Netherlands. Pulmonologists
and internists expressed their level of agreement with statements on ordering capillary
glucose testing and treatment initiation.
Results: Respondents ordered screening for GCIH in 85% of vignette patients and initiated
treatment in 56%. When initiating treatment, respondents opt for sliding scale insulin in
62% of patients. Sliding scale insulin was more frequently prescribed in patients with pre-
existent insulin dependent diabetes (OR 2.4, CI 1.3–4.2) and by residents (vs. specialists, OR
2.1, CI 1.2–3.5). Sixty-nine percent of clinicians experienced a lack of guidelines for GCIH.
Conclusions: Clinicians have a strong tendency to screen for GCIH but subsequent initiation
of treatment was low. Sliding scale insulin is still widely used in episodic GCIH despite
evidence against its effectiveness. This may be due to lacking evidence on feasible treatment
options for GCIH.
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Temporary high dose glucocorticoid therapy (‘pulse therapy’)
is complicated by hyperglycaemia in 42–69% of patients [1,2].
Synthetic glucocorticoids have similar biologic activity as
endogenous cortisol. Cortisol induces peripheral insulin
resistance, diminishes insulin production and secretion and
stimulates endogenous glucose production [3,4]. Glucocorti-
coids are frequently used in treatment of COPD exacerbation
and autoimmune disorders and as a component of antineo-
plastic chemotherapy. The effect of pulse therapy on glucose
metabolism is dose dependent and often transient [5,6].
Glucocorticoid induced hyperglycaemia (GCIH) is associat-
ed with adverse clinical outcomes in patients treated for COPD
exacerbation, patients receiving chemotherapy and patients
with other intercurrent illnesses requiring glucocorticoid
therapy [7–9]. From preclinical studies, it can be hypothesized
that hyperglycaemia leads to adverse outcomes by inducing a
procoagulant state and impaired functioning of the immune
system [10,11]. Treating in-hospital hyperglycaemia is likely to
have short- and long-term beneficial effects [12,13]. However,
in the absence of evidence for effective treatment regimens for
GCIH episodes, current practice depends on local protocols
and habits of individual clinicians.
Our aim is to explore the current practice of screening for
GCIH, the intention to start treatment for hyperglycaemia and
the treatment choice in patients receiving glucocorticoid pulse
therapy.
2. Methods
We studied clinician’s decision-making in a factorial survey
[14]. We designed written case vignettes of fictive patients
receiving glucocorticoid pulse therapy either as a part of
chemotherapeutic regimen or as treatment for COPD exacer-
bation for 5–12 days.Fig. 1 – Example of a writCase vignettes varied on 8 characteristics (factors), namely
age, gender, diabetes status, history of GCIH, admission status,
duration of pulse therapy, glucose level before start and during
pulse therapy. Combining all factors resulted in 256 case
vignettes. We excluded unrealistic vignettes, ending up with
176 different vignettes. Strict control was defined as target
glucose <10 mmol/l according to guidelines for non-critically
ill patients [12,13].
We asked respondents to rate a random hard-copy sample
of 8 different vignettes and we investigated respondents’
attitudes on episodic GCIH. Response options were in multiple
choice format or 1 till 6 Likert scale (Fig. 1). Applicability of the
survey was evaluated by the think-aloud technique [15]. We
actively recruited internists and pulmonologists on 2 nation-
wide conferences and in hospitals across the Netherlands.
We analysed the predictive value of vignette factors and
clinician’s characteristics on the respondent’s decisions in an
ordinal regression model. Therapy options were analysed as
dummy outcome variables in a logistic regression model.
Results of regression analysis are expressed as odds ratios and
95% confidence interval (OR, 95% CI). In the ordinal regression
model, a higher odds ratio indicates that clinicians have a
higher chance to agree with a specific decision as compared to
when the predictor variable is not present. Confidence
intervals were adjusted for the fact that respondents rated
multiple vignettes by a generalized estimating equation. We
performed all analyses in SPSS version 21 and vignettes were
generated in MS Excel 2003.
3. Results
3.1. General characteristics of respondents
Between November 2013 and May 2014, we received response
from 106 clinicians (70% internal medicine, 30% pulmonology,
response rate 42%) from 31 different secondary and tertiary
teaching hospitals. Respondents were employed in theten patient vignette.
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specialist (65%) and others were resident (29%) or diabetes
nurse (6%).
3.2. Screening
Clinicians were more likely to order capillary glucose testing
for GCIH in patients with pre-existent type 2 diabetes (OR 3.5,
CI 2.3–5.4), in patients with random hyperglycaemia before
onset of glucocorticoid therapy (OR 2.9, CI 2.1–4.0) and in
patients who were hospitalized (OR 1.7, CI 1.2–2.3) as
compared to patients without these risk factors (Fig. 2).
Unsurprisingly, clinicians who aimed at strict glycaemic
control during glucocorticoid pulse therapy had a stronger
tendency to order capillary glucose testing (OR 2.1, CI 1.5–2.9)
as compared to clinicians who aimed at more lenient glucose
levels. Age and sex of the patient and also former episodes
GCIH did not contribute to the decision to screen for GCIH.
3.3. Augmentation of glucose lowering therapy
Fifty-five percent of respondents indicated to aim at more
lenient glucose targets than advised in guidelines for
glycaemic control in non-critically ill patients [12,13]. More
specialists (68%) than residents (35%) indicated to aim at
lenient glucose targets. Sixty-nine percent of respondents
declared that there is a lack of evidence for treatment of GCIH.
In total, in 55.5% of GCIH-cases respondents intended to
initiate or augment glucose lowering treatment (Fig. 3). The
strongest predictor for the decision to adjust treatment for
transient GCIH was the severity of hyperglycaemia in the
capillary glucose curve. Twenty-two percent of all respon-
dents started treatment for patients with a slightly elevated
glucose curve, which increased to 92% for patients with the
highest glucose curve. Other factors that made clinicians
adjust glucose lowering treatment were being diagnosed withFig. 2 – Decision to screen for GCIH. The Bars indicate the level
capillary glucose testing to diagnose GCIH. The level of agreeme
left column. A * indicates the factors that significantly influence 
model ( p < 0.05).diabetes (OR 2.0, CI 1.4–2.9), longer duration of glucocorticoid
pulse therapy (OR 1.6, CI 1.2–2.2) and being treated by a
physician aiming at strict glucose levels during episodic GCIH
(OR 2.0, CI 1.5–2.7). The decision whether or not to adjust
treatment for episodic GCIH was not affected by admission
status of the patient or the clinician’s vigilance for hypogly-
caemia during treatment of GCIH.
3.4. Treatment modality
If glucose lowering treatment was considered necessary,
subcutaneous sliding scale insulin (SSI) with short acting
insulin was chosen in 62% of the vignettes followed by oral
glucose lowering agents (18%) and other insulin regimens
(19%) (Fig. 4). Respondents frequently used the free text option
to choose for non-pharmacologic strategies like a watch and
wait policy or pulmonologists consulting an internist for
treatment advice.
Within the subset of vignettes in which a treatment was
prescribed, the strongest trigger to prescribe SSI instead of
other treatments (i.e. other insulin regimens or oral agents)
was pre-existent insulin treated type 2 diabetes (OR 2.4, CI 1.3–
4.2). Hospitalization was another trigger to prescribe SSI (OR
1.9, CI 1.3–3.0). Furthermore, residents were twice more likely
to prescribe SSI than specialists (OR 2.1, CI 1.2–3.5).
The clinician’s concern for hypoglycaemia during treat-
ment of episodic GCIH was not explanatory for the choice for
SSI (OR 0.7, CI 0.4–1.0). We saw a trend that clinicians who said
not to encounter problems with treatment of GCIH and not to
experience a lack of guidelines for GCIH were more likely to
prescribe SSI (OR 1.3, CI 0.9–2.0 and OR 1.6, CI 0.99–2.5).
In the group that was diabetes treatment-naı¨ve, clinicians
started oral glucose lowering agents in 31% of cases (27%
metformin and 4% sulfonylurea) and that fraction of oral
therapy increased when hyperglycaemia was present before
onset of pulse therapy (OR 2.4, CI 1.3–4.2). of agreement of the clinicians with the statement to order
nt is split up for the patient and respondent factors in the
the decision process in the multivariate ordinal regression
Fig. 3 – Decision to initiate treatment for GCIH. The bars indicate the level of agreement of the clinicians with the statement
to start treatment for GCIH. The level of agreement is split up for the patient and respondent factors in the left column. A *
indicates the factors that significantly influence the decision process in the multivariate ordinal regression model ( p < 0.05).
Fig. 4 – Choice of treatment type. A bar represents all respondents who choose to initiate treatment and the colors represent
the fractions choosing a specific treatment modality. The different columns indicate how the choices differ for different
patient and respondent characteristics.
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Our survey shows that SSI still is widely used in GCIH,
especially in hospitalized patients treated by less experienced
clinicians. We conclude that GCIH is recognized as a clinically
significant condition as indicated by the high rate of screening
for GCIH, but tendency to respond to transient hyperglycaemia
by initiating or augmenting glucose lowering treatment was
considerably lower. A factor contributing to this discrepancy
may be that the majority of clinicians indicated to experience a
lack of evidence for management of GCIH.
A strength of our study is the factorial survey method.
Decisions in written case vignettes were shown to be
representative for ‘real-world’ clinical practice [16]. A limita-
tion is the response rate of 42%. Responding clinicians
probably have a greater interest in the topic of GCIH as
compared to non-responding clinicians. This may have
resulted to a higher tendency to screen and treat GCIH than
realworld practice.
A pre-existent diagnosis of diabetes mellitus was overall a
strong incentive for decisions regarding screening as well as
treatment of GCIH. We hypothesize that higher glucose
excursions are expected in patients with diabetes that are
treated with glucocorticoids. However, severe hyperglycaemia
may very well occur in patients without a known diagnosis of
diabetes and is more strongly associated with adverse
outcomes in this group [17,18]. If clinicians initiated treatment
in patients not previously diagnosed with diabetes, they had a
preference for oral glucose lowering agents. This practice may
reflect the chance of triggering type 2 diabetes by glucocorti-
coid therapy but it does not counter possible acute adverse
effects of stress-hyperglycaemia [19].
The outcome that SSI is still widely used is consistent with
previous findings that it is difficult to ban SSI from clinical
practice [20,21]. The first study indicating that SSI insulin is not
effective for improving glycaemic control originates in the
1970s and was confirmed in more recent studies [22,23]. Even
SSI as add-on treatment to routine glucose lowering agents
has no clear benefit above routine medication only [24]. Our
finding that clinicians who declare not to experience problems
with treatment of GCIH had a stronger preference for SSI
supports the notion that SSI is used more to ‘fix the number’
instead of intending to improve patient outcomes. It indicates
a certain clinical inertia for glucose management in non-
critically ill patients.
A possible reason for the persistence of SSI in daily practice
is the lack of evidence for alternative effective and feasible
treatment options. Review articles advocate screening for
GCIH in patients with and without diabetes, pursuing glucose
targets <10 mmol/l, treatment with insulin but discourage SSI
without basal insulin [13,20]. One study found that the insulin
requirement in subjects on prednisone 60 mg per day
increased by 0.35 IU/kg body weight (69% increase compared
to before prednisone therapy) and these requirements are not
met with most subcutaneous SSI regimens [25,26].
Most guidelines recommend to discontinue all noninsulin
glucose lowering agents in GCIH and stress hyperglycaemia
for safety reasons. This is unfortunate since metformin with
its capacity to counter insulin resistance might especially beeffective in GCIH [27]. The safety concern originates from the
perceived relationship between metformin and lactic-acidosis
and this perception is fed by incidental case-reports [28].
However, the incidence of lactic-acidosis during metformin is
equal to other glucose-lowering treatment modalities and a
causal relationship is not established [29,30]. Discontinuing
metformin is not recommended in Dutch guidelines – except
when there are contraindications e.g., severe kidney disease or
shock – and indeed none of our respondents chose to
discontinue metformin in patients diagnosed with diabetes
on glucocorticoid therapy [31].
We recommend to continue routine glucose lowering
agents during GCIH as long as there are no contraindications
and to augment routine therapy in case of insufficient
glycaemic control. Acute and chronic kidney disease should
be taken into account. Metformin and sulfonylureas them-
selves are not nephrotoxic but accumulation of these agents
may occur if the glomerular filtration rate is less than 45 mL/
min. In case of severe kidney disease, oral glucose lowering
agents should be discontinued or administered in a reduced
dose. If glycaemic control is suboptimal under the routine
agents, insulin therapy should be initiated or augmented.
Depending on the level of pre-existing and increased insulin
resistance during glucocorticoid pulse therapy, the extra
insulin requirement varies between 0.2 and 0.5 IU/kg [26].
Following the circadian pattern of GCIH, extra insulin should
be targeted at afternoon and evening hours during which
hyperglycaemia is more pronounced [32]. This can be achieved
by administering intermediate-long acting insulin in the
morning as add-on to existing glucose lowering treatment
[33–35]. Another way to cover afternoon and evening is to
augment or initiate prandial insulin by 0.2–0.5 IU/kg. The
distribution of extra prandial insulin over the day should be
approximately 1:4:5 for breakfast, lunch and dinner. Evidence
on treatment of GCIH with incretin-based therapies and SGLT-
2 inhibitors is emerging and these agents may become part of
the therapeutic arsenal in future [36–38].
To conclude, clinicians have a strong tendency to screen
and to initiate treatment for glucocorticoid induced hypergly-
caemia. However, many clinicians still opt for ineffective SSI
regimens to treat glucocorticoid induced hyperglycaemia.
Future studies should focus on the outcome of glucose
lowering treatment and on the development of safe, effica-
cious and easy-to-implement treatment options, to be used
when glucose lowering treatment is indicated.
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